Albuterol inhaler grams
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Inhaler Dosage and Efficacy: A Comprehensive Review
Introduction to Albuterol Inhalers
Albuterol, a short-acting beta2-agonist (SABA), is commonly used for the relief of bronchospasm in conditions such as asthma. It is available in various forms, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizer solutions. This article synthesizes research findings on the dosage, efficacy, and safety of albuterol inhalers.
Dosage and Bronchodilator Response
Metered-Dose Inhalers (MDIs)
Studies have shown that the bronchodilator response to albuterol increases with the number of inhalations. In a study involving 44 asthmatic patients, significant improvements in forced expiratory volume in one second (FEV1) were observed with increasing doses of albuterol from MDIs, with four, six, and eight inhalations providing greater bronchodilation compared to a single inhalation1. Another study confirmed that albuterol delivered via MDI provided similar bronchodilation to that achieved by wet nebulization, with about one-sixth the dose of nebulized albuterol needed to achieve a similar response3.
Dry Powder Inhalers (DPIs)
Albuterol delivered via a multidose dry powder inhaler (MDPI) has also been shown to be effective. In a study with pediatric patients, both 90 mcg and 180 mcg doses of albuterol MDPI significantly improved pulmonary function compared to placebo, with no new safety concerns noted5. The safety profile of albuterol MDPI was comparable to that of placebo and consistent with the well-characterized profile of albuterol8.
Nebulizers
Nebulized albuterol is often used in acute settings. A study comparing 2.5 mg and 7.5 mg doses of nebulized albuterol found no significant difference in the improvement of FEV1 or admission rates between the two doses, suggesting that higher doses may not provide additional benefits in most patients10. Another study indicated that higher doses of nebulized albuterol delivered more drug to lung receptors compared to lower doses from MDIs6.
Combination Therapy
Albuterol and Budesonide
Combining albuterol with an inhaled corticosteroid like budesonide can address both bronchoconstriction and inflammation. A phase 3 trial demonstrated that a fixed-dose combination of albuterol and budesonide significantly reduced the risk of severe asthma exacerbations compared to albuterol alone2. This combination therapy was effective in both adults and children with moderate-to-severe asthma4.
Albuterol and Beclomethasone
In patients with mild asthma, the symptom-driven use of a combination of beclomethasone and albuterol in a single inhaler was found to be as effective as the regular use of inhaled beclomethasone, with a lower cumulative dose of the corticosteroid over six months7.
Conclusion
Albuterol inhalers, whether delivered via MDIs, DPIs, or nebulizers, are effective in managing asthma symptoms. The optimal dose varies depending on the delivery method, with MDIs and DPIs requiring lower doses compared to nebulizers for similar efficacy. Combination therapies with corticosteroids like budesonide or beclomethasone offer additional benefits by reducing inflammation and the risk of severe exacerbations. These findings underscore the importance of personalized treatment plans to achieve maximum bronchodilation and control of asthma symptoms.
Sources and full results
Most relevant research papers on this topic
The bronchodilator response to inhalation of increasing doses of aerosolized albuterol.
Maximum bronchodilation in asthmatic patients is not achieved by customarily recommended doses, with four, six, and eight inhalations from a metered dose inhaler and 15 mg by IPPB being significantly greater than any other dose.
RCTAlbuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
A fixed-dose combination of 180 g of albuterol and 160 g of budesonide significantly reduces the risk of severe asthma exacerbation compared to albuterol alone in patients with uncontrolled moderate-to-severe asthma.
RCT
Large Human Trial
Rigorous JournalA comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma.
Albuterol administered by metered dose inhaler provided similar bronchodilation to that achieved by wet nebulization in patients with acute asthma.
RCT
Highly CitedEfficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study
As-needed albuterol/budesonide versus albuterol as rescue therapy effectively reduces asthma exacerbations and improves bronchoconstriction control in adults and children aged 4 years with moderate-to-severe asthma.
RCTLarge Human TrialRigorous JournalDose-Ranging Efficacy and Safety Study of Albuterol Multidose Dry Powder Inhaler (MDPI) vs Albuterol Hydrofluoroalkane (HFA) and Placebo MDPI in Children With Asthma
Albuterol MDPI significantly improves pulmonary function in children with asthma, with similar effects to albuterol HFA, and its safety profile is consistent with that of albuterol HFA.
RCTRigorous JournalRelative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation.
Higher doses of albuterol nebulizer solution deliver more to beta 2 receptors in the lung than lower doses from metered-dose inhalers, affecting clinical response.
RCTRescue use of beclomethasone and albuterol in a single inhaler for mild asthma.
Symptom-driven use of inhaled beclomethasone and albuterol in a single inhaler is as effective as regular use and associated with a lower cumulative dose of inhaled corticosteroid.
RCTLarge Human TrialHighly CitedTwelve- and 52-week safety of albuterol multidose dry powder inhaler in patients with persistent asthma
The albuterol MDPI 180 g inhaler has a comparable safety profile to placebo in patients with persistent asthma, with the most common adverse events being nasopharyngitis, sinusitis, and upper respiratory tract infection.
RCTLarge Human TrialTreatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder.
Inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder is effective in treating acute severe asthma, with no significant differences in response between the three methods.
RCTHighly Cited